Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alprazolam

FDA-approved product (tablet, oral), marketed as Alprazolam, Niravam, Xanax and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Alprazolam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety
  • Anxiety disorder
  • Generalized anxiety disorder
  • Panic disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alprazolam in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alprazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of Chronic Migraine Headaches.

    NCT03220113 · start 2017-07-01

    Registered record
    Registry ID
    NCT03220113
    Conditions
    Chronic Migraine Without Aura, Intractable; Migraine With Typical Aura; Migraine Disorders
    Interventions
    Dexamethasone, Lidocaine, Thiamine cohort
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2017-07-01
    Completion
    2019-07-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Migraine Without Aura, Intractable; Migraine With Typical Aura; Migraine Disorders
    InterventionDexamethasone, Lidocaine, Thiamine cohort
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

    NCT03509285 · start 2017-03-08

    Registered record
    Registry ID
    NCT03509285
    Conditions
    Healthy Volunteer
    Interventions
    Alprazolam Placebo; Cenobamate placebo; Alprazolam; Cenobamate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-08
    Completion
    2017-12-15
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionAlprazolam Placebo; Cenobamate placebo; Alprazolam; Cenobamate
    PhasePhase 1
    Registry statusCompleted

  • Opiates and Benzodiazepines on Driving

    NCT03447353 · start 2016-06-14

    Registered record
    Registry ID
    NCT03447353
    Conditions
    Driving Behavior
    Interventions
    Xanax 1Mg Tablet; Norco 10Mg-325Mg Tablet; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-06-14
    Completion
    2016-10-25
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDriving Behavior
    InterventionXanax 1Mg Tablet; Norco 10Mg-325Mg Tablet; Placebo Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety.

    NCT03702803 · start 2016-03-16

    Registered record
    Registry ID
    NCT03702803
    Conditions
    Generalized Anxiety Disorder
    Interventions
    Galphimia glauca standardized extract; alprazolam 1mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-03-16
    Completion
    2020-10-19
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionGalphimia glauca standardized extract; alprazolam 1mg
    PhasePhase 2
    Registry statusUnknown

  • Gabapentin Treatment of Benzodiazepine Dependence

    NCT01893632 · start 2013-07

    Registered record
    Registry ID
    NCT01893632
    Conditions
    Benzodiazepine Dependence
    Interventions
    gabapentin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2016-04-01
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenzodiazepine Dependence
    Interventiongabapentin; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T

    NCT01747590 · start 2011-07

    Registered record
    Registry ID
    NCT01747590
    Conditions
    Psychotropic Drugs Effects
    Interventions
    Zolpidem; Alprazolam; Caffeine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2011-07
    Completion
    2013-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotropic Drugs Effects
    InterventionZolpidem; Alprazolam; Caffeine; Placebo
    PhaseEarly phase 1
    Registry statusUnknown

  • Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation

    NCT01027689 · start 2011-04

    Registered record
    Registry ID
    NCT01027689
    Conditions
    Healthy
    Interventions
    alprazolam commercial immediate release oral tablet; alprazolam test sublingual tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2011-04
    Completion
    2011-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionalprazolam commercial immediate release oral tablet; alprazolam test sublingual tablet
    PhasePhase 1
    Registry statusWithdrawn

  • Effect of Alprazolam on the Success of Inferior Alveolar Nerve (IAN) Block

    NCT01546090 · start 2011-03

    Registered record
    Registry ID
    NCT01546090
    Conditions
    Inferior Alveolar Nerve Block Failure
    Interventions
    Alprazolam; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInferior Alveolar Nerve Block Failure
    InterventionAlprazolam; placebo
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

    NCT01256151 · start 2011-01

    Registered record
    Registry ID
    NCT01256151
    Conditions
    Anxiety Disorder
    Interventions
    Alprazolam tablet; Alprazolam sublingual
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-05
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorder
    InterventionAlprazolam tablet; Alprazolam sublingual
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Trial of Alprazolam 0.5 mg Tablets

    NCT01745562 · start 2010-12-07

    Registered record
    Registry ID
    NCT01745562
    Conditions
    Anxiety Disorders
    Interventions
    Alprazolam 0.5 mg; Alprazolam 0.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-12-07
    Completion
    2010-12-17
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorders
    InterventionAlprazolam 0.5 mg; Alprazolam 0.5 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions

    NCT01046162 · start 2010-07-15

    Registered record
    Registry ID
    NCT01046162
    Conditions
    Healthy
    Interventions
    Alprazolam; Alprazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2010-07-15
    Completion
    2010-07-22
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAlprazolam; Alprazolam
    PhasePhase 1
    Registry statusWithdrawn

  • Bioequivalence Trial of Alprazolam 2 mg Tablets

    NCT01745575 · start 2010-03-28

    Registered record
    Registry ID
    NCT01745575
    Conditions
    Anxiety Disorders
    Interventions
    Alprazolam 2mg tablets; Alprazolam 2 mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03-28
    Completion
    2010-04-05
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorders
    InterventionAlprazolam 2mg tablets; Alprazolam 2 mg tablets
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence of Alprazolam Sublingual vs Oral Tablets

    NCT00860119 · start 2009-08

    Registered record
    Registry ID
    NCT00860119
    Conditions
    Healthy
    Interventions
    alprazolam sublingual tablet; alprazolam oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    2009-10
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionalprazolam sublingual tablet; alprazolam oral tablet
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets

    NCT00878865 · start 2009-04

    Registered record
    Registry ID
    NCT00878865
    Conditions
    Healthy
    Interventions
    Alprazolam; Alprazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAlprazolam; Alprazolam
    PhasePhase 1
    Registry statusCompleted

  • Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder

    NCT00662259 · start 2008-04

    Registered record
    Registry ID
    NCT00662259
    Conditions
    Generalized Anxiety Disorder
    Interventions
    Alprazolam (Xanax); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-04
    Completion
    2009-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionAlprazolam (Xanax); Placebo
    PhasePhase 4
    Registry statusCompleted